TipRanks on MSN

Immutep highlights progress in TACTI-004 Phase III cancer trial

An announcement from Immutep ( ($IMMP) ) is now available. Immutep Limited announced significant advancements in its global TACTI-004 Phase III ...

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress ...
Seeking Alpha

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved ...
Nasdaq

Immutep Limited to Present TACTI-004 Phase III Trial Data at European Lung Cancer Congress 2025

Immutep Limited announces a poster presentation on the TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. Immutep Limited announced an upcoming poster presentation for its pivotal ...
Forbes

What's The Difference Between Sales Activation And Brand-Building?

Any time you talk about sales or branding, one thing probably comes to mind: connecting with more customers so you can sell more products or services. After all, that is the point of any marketing ...